A Prospective Observational Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus

NCT ID: NCT02158078

Last Updated: 2016-07-26

Basic Information

• Recruitment Status: TERMINATED
• Total Enrollment: 8 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2014-06-30
• Study Completion Date: 2014-11-30

Brief Summary

The purpose of the study is to obtain an assessment (efficacy, safety, and patient reported outcomes) of basal bolus insulin delivery with PaQ in insulin-using patients with type 2 diabetes mellitus (T2DM).

Detailed Description

This is a prospective, single center, post-market observational study to assess the efficacy, safety, and patient reported outcomes of insulin delivery with PaQ® in patients with type 2 diabetes mellitus (T2DM) who are currently receiving basal/bolus insulin therapy with or without oral anti-diabetic drugs (OADs) for glycemic control. The patient's participation in the study is comprised of three phases: screening/baseline evaluation, transition to PaQ use and optimization, and PaQ treatment period. The use of these phases will allow an orderly transition to PaQ treatment as well as a reliable construct from which to interpret the final data.

Conditions

Type 2 Diabetes Mellitus

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Interventions

PaQ® Insulin Delivery Device

PaQ is a 3 day insulin delivery device. Utilizes U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Is at least 18 years of age
• Has a clinical diagnosis of T2DM, as determined by clinical history and medication usage
• Has an A1C ≥ 7.0% and ≤ 11.0%;
• Is treated with basal-bolus insulin therapy (at least 2 injections per day) with or without OADs, and/or glucagon-like peptide-1 (GLP-1) agonist for at least 3 months and has not had a change (addition or discontinuation of existing drug or change in dose) in their OADs for the last 8 weeks
• Determined by the investigator that insulin requirements to achieve glycemic targets can be met by the insulin capacity of the PaQ device
• If on concomitant metformin, has serum creatinine <1.5 mg/dL (male) or <1.4 mg/dL (female)
• If female, and of child-bearing potential, has a negative urine pregnancy test at screening and must be using adequate means of contraception as determined by the Investigator
• Is clinically euthyroid as judged by the Investigator
• Is able to understand and sign the required study documents and comply with the clinical investigational plan (CIP) requirements
• Is deemed capable by the Investigator to perform the requirements of the CIP, including use of PaQ, frequent self-monitoring of blood glucose

Exclusion Criteria

• Is poorly compliant with the currently prescribed diabetes regimen, as determined by the Investigator
• Is poorly compliant with prescribed self-monitoring of blood glucose, as determined by the Investigator
• Is currently taking or has taken sulfonylureas within the last 2 months
• Has a BMI greater than 40 kg/m2
• Has experienced recurrent severe hypoglycemia (> 2 episodes) requiring assistance during the past 6 months
• Has existing dermal irritation/inflammation over the abdominal area that may interfere with use of PaQ, as determined by the Investigator
• Has known clinically significant hypersensitivity to skin adhesives
• Is female and if of child-bearing potential, is pregnant, lactating, or planning to become pregnant
• Is currently being treated with or expected to require or undergo treatment with systemic steroids by oral, intravenous, or intramuscular route (inhaled with low systemic exposure is permitted)
• Currently abuses drugs or alcohol or has a history of abuse that in the Investigator's opinion would cause the individual to be non-compliant
• Has received any investigational drug within 1 month
• Has donated blood within 30 days
• Has any significant medical condition (including current or past history of cardiovascular disease), laboratory findings, or medical history that in the Investigator's opinion may affect successful completion of the study and/or personal well-being
• Is an immediate family member (spouse, parent, child, or sibling) of personnel directly affiliated with the study at the investigative site, or is personally directly affiliated with the study at the investigative site

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CeQur Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Thomas Pieber, MD

Role: PRINCIPAL_INVESTIGATOR

Medical University of Graz

Locations

Medical University of Graz

Graz, , Austria

Countries

Austria

References

Mader JK, Lilly LC, Aberer F, Poettler T, Johns D, Trautmann M, Warner JL, Pieber TR. Improved glycaemic control and treatment satisfaction with a simple wearable 3-day insulin delivery device among people with Type 2 diabetes. Diabet Med. 2018 Oct;35(10):1448-1456. doi: 10.1111/dme.13708. Epub 2018 Jul 5.

Reference Type: DERIVED

PMID: 29888811 (View on PubMed)

Other Identifiers

CQR13002

Identifier Type: -

Identifier Source: org_study_id